Immuneering Corporation

Immuneering Corporation is a clinical-stage biotechnology company that is engaged in the development of novel cancer immunotherapy products to disrupt the tumour microenvironment and restore the immune system’s ability to eliminate cancer cells. Operating in the healthcare sector, Immuneering’s platform is designed to identify and target novel immune checkpoints that play a critical role in cancer progression. The company’s lead product, IMM-1-104, is a first-in-class oral therapy that targets RAS mutations, the most common genetic alterations found in human cancers. Diversify your virtual portfolio by following IMRX shares on eToro.